Articles

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria;Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria;Department of Radiation Therapy, Medical University of Vienna, Austria
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
Department of Laboratory Medicine, Medical University of Vienna, Austria
Children’s Cancer Research Institute (CCRI), Vienna, Austria
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria;Department of Laboratory Medicine, Medical University of Vienna, Austria
Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Institute of Drug Delivery Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan
Department of Chemistry, University of Toronto, Canada
Department of Chemistry, University of Toronto, Canada
Institute of Drug Delivery Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan
Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria;Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Children’s Cancer Research Institute (CCRI), Vienna, Austria;Department of Pediatrics, Medical University of Vienna, Austria
Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria;Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria
Vol. 102 No. 9 (2017): September, 2017 https://doi.org/10.3324/haematol.2016.163436